CD274 and non-small cell lung carcinoma: This was followed by the EMA, which recognised the clinical benefit of durvalumab in adults with stable unresectable stage III NSCLC following two or more cycles of platinum-based cCRT, whose tumours express PD-L1 on ≥1% of tumour.38